Twist Bioscience IPO

Twist Bioscience is a synthetic biology company that manufactures synthetic DNA using a proprietary silicon-based DNA synthesis platform. Unlike traditional DNA synthesis methods that use plastic plates, Twist's technology writes DNA on silicon chips, enabling massive parallelization and higher quality synthesis at scale. The company serves pharmaceutical, agricultural, academic, and industrial biotechnology customers who need custom DNA sequences for drug discovery, synthetic biology applications, and research.

The company has expanded beyond basic DNA synthesis into higher-value applications including antibody discovery, where they create synthetic antibody libraries for pharmaceutical companies, and data storage, where they encode digital information in DNA. Twist went public in 2018 and has positioned itself as a critical infrastructure provider for the growing synthetic biology industry, with the potential to accelerate everything from vaccine development to sustainable chemical production.